Immunogenicity of trivalent DNA vaccine candidate encapsulated in Chitosan-TPP nanoparticles against EV-A71 and CV-A16.

Nanomedicine (London, England) Pub Date : 2024-01-01 Epub Date: 2024-08-14 DOI:10.1080/17435889.2024.2372243
Jia Sheng Yew, Seng-Kai Ong, Hui Xuan Lim, Soon Hao Tan, Kien Chai Ong, Kum Thong Wong, Chit Laa Poh
{"title":"Immunogenicity of trivalent DNA vaccine candidate encapsulated in Chitosan-TPP nanoparticles against EV-A71 and CV-A16.","authors":"Jia Sheng Yew, Seng-Kai Ong, Hui Xuan Lim, Soon Hao Tan, Kien Chai Ong, Kum Thong Wong, Chit Laa Poh","doi":"10.1080/17435889.2024.2372243","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> To develop a trivalent DNA vaccine candidate encapsulated in Chitosan-TPP nanoparticles against hand foot and mouth disease (HFMD) and assess its immunogenicity in mice.<b>Materials & methods:</b> Trivalent plasmid carrying the VP1 and VP2 genes of EV-A71, VP1 gene of CV-A16 was encapsulated in Chitosan-TPP nanoparticles through ionic gelation. <i>In vitro</i> characterization and <i>in vivo</i> immunization studies of the CS-TPP-NPs (pIRES-VP121) were performed.<b>Results:</b> Mice administered with CS-TPP NPs (pIRES-VP121) intramuscularly were observed to have the highest IFN-γ response. Sera from mice immunized with the naked pDNA and CS-TPP-NPs (pIRES-VP121) demonstrated good viral clearance against wild-type EV-A71 and CV-A16 in RD cells.<b>Conclusion:</b> CS-TPP-NPs (pIRES-VP121) could serve as a prototype for future development of multivalent HFMD DNA vaccine candidates.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418279/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17435889.2024.2372243","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/14 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: To develop a trivalent DNA vaccine candidate encapsulated in Chitosan-TPP nanoparticles against hand foot and mouth disease (HFMD) and assess its immunogenicity in mice.Materials & methods: Trivalent plasmid carrying the VP1 and VP2 genes of EV-A71, VP1 gene of CV-A16 was encapsulated in Chitosan-TPP nanoparticles through ionic gelation. In vitro characterization and in vivo immunization studies of the CS-TPP-NPs (pIRES-VP121) were performed.Results: Mice administered with CS-TPP NPs (pIRES-VP121) intramuscularly were observed to have the highest IFN-γ response. Sera from mice immunized with the naked pDNA and CS-TPP-NPs (pIRES-VP121) demonstrated good viral clearance against wild-type EV-A71 and CV-A16 in RD cells.Conclusion: CS-TPP-NPs (pIRES-VP121) could serve as a prototype for future development of multivalent HFMD DNA vaccine candidates.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
壳聚糖-TPP 纳米颗粒封装的三价 DNA 候选疫苗对 EV-A71 和 CV-A16 的免疫原性。
目的:开发一种包裹在壳聚糖-TPP 纳米颗粒中的手足口病三价 DNA 候选疫苗,并评估其在小鼠体内的免疫原性。材料与方法:通过离子凝胶化将携带 EV-A71 的 VP1 和 VP2 基因、CV-A16 的 VP1 基因的三价质粒封装在壳聚糖-TPP 纳米颗粒中。对 CS-TPP-NPs (pIRES-VP121)进行了体外表征和体内免疫研究。研究结果肌肉注射 CS-TPP NPs(pIRES-VP121)的小鼠对 IFN-γ 的反应最高。用裸 pDNA 和 CS-TPP-NPs (pIRES-VP121) 免疫小鼠的血清显示出对 RD 细胞中野生型 EV-A71 和 CV-A16 病毒的良好清除率。结论:CS-TPP-NPs(pIRES-VP121CS-TPP-NPs (pIRES-VP121) 可作为未来开发多价手足口病 DNA 候选疫苗的原型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Applying the lessons learned from the COVID-19 pandemic to the next generation of nanocarrier-based vaccines. The potential of ceramic nanomaterials in preventive dentistry. Pluronic F127/lecithin PLGA nanoparticles as carriers of monocyte-targeted jakinibs: a potential therapeutic platform. Hispolon-loaded lipid nanocapsules for the management of hepatocellular carcinoma: comparative study with solid lipid nanoparticles and suspension. Nanoformulations of amphotericin B to resolve challenges in antifungal therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1